Antibodies for use in antilymphocyte antibody therapy
AssigneeCelltech Limited
InventorWim Buurman
Life of this patent
Estimating the term…
Abstract
The use of antibodies against human alpha tumor necrosis factor in antilymphocyte antibody therapy is described. The anti-human alpha tumor necrosis factor antibodies may be used to prevent or treat shock-related conditions arising from antilymphocyte antibody therapy. Also described are compositions containing anti-human alpha tumor necrosis factor antibodies and antilymphocyte antibodies, as well as recombinant anti-human alpha tumor necrosis factor antibodies.
Claims8
A pharmaceutical composition which comprises an antibody against human .alpha.-tumour necrosis and an antilymphocyte antibody in admixture with one or more pharmaceutically acceptable carriers, excipients or diluents.
A two component system, each component for use in association with one another in antilymphocyte antibody therapy, said system comprising (1) a first component that is an antinbody against human .alpha.-tumour necrosis factor, and (2) a second component that is an antilymphocyte antibody.
A method of treatment of a human subject suffering from an immunoregulatory disorder amenable to treatment by antilymphocyte antibody therapy which comprises administering to said human subject an effective amount of an anti-TNF.alpha. antibody in association with an antilymphocyte antibody.
A method of treatment of a human subject suffering from a shock condition arising from antilymphocyte antibody therapy which comprises administering an effective amount of an antibody against human .alpha.-tumor necrosis factor to the human subject.
A method for the prevention or treatment of shock-related conditions arising from antilymphocyte antibody therapy comprising administering to a person in need of same an effective amount of an antibody against human .alpha.-tumor necrosis factor.
Dependencies are inferred from the claim text.